Omeprazole Overuse and Its Financial Loss in a Community Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To determine prevalence of omeprazole overuse and its financial loss in outpatients in a community hospital in urban area. Method: This study collected the data retrospectively from electronic database of the hospital by retrieving the data of outpatients receiving omeprazole during January 1, 2012 to December 31, 2016. Appropriate drug use was defined as the use that was consistent to US-FDA approved indications or various guidelines’ recommendation. Result: A total number of outpatients who received omeprazole was 6,427 cases with 24,568 visits. Most patients’ visits were under the Universal Coverage Schemes (70.43%). As a result, the Scheme incurred the highest total financial loss accounting for approximately 75 percent of the total loss. However, the average financial loss per visit was not different among patients under different health insurances. A total of 17,192 out of 24,568 omeprazole prescribing (69.98%) was considered as medication overuse. The financial loss due to omeprazole overuse was 401,402 Thai baht over 5 years or 80,208 baht per year. The average financial loss per visit was 23.35±18.12 baht. Conclusion: Most of omeprazole use in community hospital setting is overuse. Percentages of omeprazole overuse are slightly different among patients under different health insurances. However, the total financial loss is relatively low because this study focused on a single drug. Financial loss might be much higher if we study the whole medication. Moreover, measures such as prospective drug utilization review or practice guideline for rational use of omeprazole might save hospital expenses..
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Doungngern T, Ngosurachat S. Efficacy and safety of proton pump inhibitors [online]. 2013 [cited Oct 1, 2016]. Available from: www.hisro.or.th/main/mo dules/research/attachservices/172/Full-text.pdf
3. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recom mendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66:1265-71.
4. Walker N, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci. 2001; 23: 116-7.
5. Mat Saad A, Collins N, Lobo M, O'Connor H. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31-4.
6. de Camargo Rocha M, Strasser M, Yanagita MLB, Ribeiro E, Campa A. Gastric acid suppressors on inpatients in a Brazilian hospital: overuse and underuse. Rev Bras Farm 2013;94:257-64
7. Health Systems Research Institute. Report on cost impact and pilot drug control measures in outpatients in direct reimbursement system for government workers during fiscal year 2009. Nonthaburi: Health Insurance System Research Office; 2010.
8. Pitragool W. Drug use review of proton pump inhibitors in a general hospital: comparison before and after intervention with managerial strategies. Thai Journal of Hospital Pharmacy 2014; 24:123-37
9. Charoenchokthavee W, Tertwattanachai T, Rodhed bhai W, Kobwanthanakun S. Analysis and manage ment of unused medications problem in urban living area. Vajira Medical Journal 2013; 57:147-60.
10. AstraZeneca Pharmaceuticals LP. Prilosec (ome prazole) delayed-release capsules and Prilosec (omeprazole magnesium) for delayed-release oral suspension revised 2014 [online] 2014. [cited Jul 8, 2016]. Available from: www.accessdata.fda.Gov/ drugsatfda_docs/label/2014/022056s017lbl019810s101lbl.pdf.
12. Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S, et al. Global perspective on gastroesophageal reflux disease. [online] 2015. [cited Jul 31, 2016]. Available from: www.worldgas troenterology.org/UserFiles/file/guidelines/gastroesophagel-reflux-disease-english-2015.pdf
13. Thaimotility, Gastroenterological Association of Thailand. Guideline for the management of GERD. [online] 2011. [cited Oct 2, 2016]. Available from: www.gastrothai.net/source/content-file/9.guideline% 20GERD.pdf
14. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383-91
15. Barry P, Barr H, Caestecker Jd, Follows M, Ford A, Jankowski J, et al. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management [online] 2014. [cited Aug 10, 2016]. Available from: www.nice.org.uk/guidance/cg184/re sources/gastrooesophageal-reflux-disease-and-dys pepsia-in-adults-investigation-and-management-pdf-35109812699845
16. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013; 108: 308 -28.
17. Gastroenterological Association of Thailand. Guide line for the management of dyspepsia & Helicobac tor pylori 2010. [online] 2011. [cited Oct 2, 2016]. Available from: www.gastrothai.net/source/content-file/12.Guideline%20dyspepsia%20and%20Helicobacter%20pylori%202010.pdf
18. Hunt R, Xiao S, Megraud F, Leon-Barua R, Bazzoli F, Van Der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guidelines; 2010.
19. Malagelada J-R, Bazzoli F, Boeckxstaens G, De Looze D, Fried M, Kahrilas P, et al. World Gastro enterology Organisation Global Guidelines: Dyspha gia. Clin J Gastroenterol. 2015;49:370-8.
20. American Gastroenterological Association. Medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140:1084-91.
21. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111 : 30-50.
22. Schlansky B, Hwang JH. Prevention of nonsteroi dal anti-inflammatory drug-induced gastropathy. Gastroenterology 2009;44:44-52.
23. Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID‐related gastrointestinal damage. Int J Clin Pract. 2005;59:1210-7.
24. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38.
25. Leandro G, Pilotto A, Franceschi M, Bertin T, Lichino E, Di Mario F. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001; 46: 1924-36.
26. Diseases of esophagus, stomach and duodenum K20-K31 [online] 2016. [cited Aug 5, 2016]. Available from: www.icd10data.com/ICD10CM/Cod es/K00-K95/K20-K31.
27. World Health Organization ICD-10. International statistical classification of diseases and related health problems 10th revision (ICD-10) [online] 2016. [cited 2016 8 Aug]. Available from: apps.who .int/classifications/icd10/browse/2016/en#/XI.
